Purpose: To determine a novel vital dye (patent blue; Blueron®) for vitreoretinal surgery in a prospective consecutive case series. Methods: Five patients with either idiopathic epiretinal membrane (ERM; n = 2), proliferative vitreoretinopathy (n = 2), or a macular hole (n = 1) underwent a three-port pars plana vitrectomy. Patent blue assisted staining of the retinal surface followed by a consecutive peeling of the ERM (n = 4) or of the internal limiting membrane (ILM; n = 1) was performed. The main outcome measures were quality of intraoperative visualization of preretinal structures and postoperative visual acuity. Results: The dye induced a moderate staining (++) of the ERM and a mild staining (+) of the ILM. Complete ERM and ILM removal was successfully achieved in all cases. A mean visual improvement of three Snellen lines was observed 6 months postoperatively. No visual field defects or visible retinal pigment epithelial changes were present 6 months postoperatively. Conclusion: Patent blue, a novel dye for intraocular applications, may be added as an alternative dye in chromovitrectomy.

Keywords:
Chromovitrectomy, Patent blue, Vital dyes
1.
Schmidt JC, Rodrigues EB, Meyer CH, Hörle S, Kroll P: A modified technique to stain the internal limiting membrane with indocyanine green. Ophthalmologica 2004;218:176–179.
2.
Sebag J: Let green lead not astray. Br J Ophthalmol 2005;89:790–792.
3.
Haritoglu C, Yu A, Freyer W, Priglinger SG, Alge C, Eibl K, May CA, Welge-Luessen U, Kampik A: An evaluation of novel vital dyes for intraocular surgery. Invest Ophthalmol Vis Sci 2005;46:3315–3322.
4.
Rodrigues EB, Meyer CH, Kroll P: Chromovitrectomy: a new field in vitreoretinal surgery. Graefes Arch Clin Exp Ophthalmol 2005;243:291–293.
5.
Kampik A, Sternberg P: Indocyanine green in vitreomacular surgery – (why) is it a problem? Am J Ophthalmol 2003;136:527–529.
6.
Rodrigues EB, Meyer CH, Farah ME, Kroll P: Intravitreal staining of the internal limiting membrane using indocyanine green in the treatment of macular holes. Ophthalmologica 2005;219:251–262.
7.
Teba FA, Mohr A, Eckardt C, Wong D, Kusaka S, Joondeph BC, Feron EJ, Stalmans P, Van Overdam K, Melles GR: Trypan blue staining in vitreoretinal surgery. Ophthalmology 2003;110:2409–2412.
8.
Schmidt JC, Meyer CH, Rodrigues EB, Hörle S, Kroll P: Staining of internal limiting membrane in vitreomacular surgery: a simplified technique. Retina 2003;23:263–264.
9.
Barranger E, Grahek D, Cortez A, Talbot JN, Uzan S, Darai E: Laparoscopic sentinel lymph node procedure using a combination of patent blue and radioisotope in women with cervical carcinoma. Cancer 2003;97:3003–3009.
10.
Hiebl W, Gunther B, Meinert H: Substances for staining biological tissues: use of dyes in ophthalmology. Klin Monatsbl Augenheilkd 2005;222:309–311.
11.
Mennel S, Thumann G, Peter S, Meyer CH, Kroll P: Influence of vital dyes on the function of the outer blood-retinal barrier in vitro. Klin Monatsbl Augenheilkd 2006; in press.
12.
Luke C, Luke M, Dietlein TS, Hueber A, Jordan J, Sickel W, Kirchhof B: Retinal tolerance to dyes. Br J Ophthalmol 2005;89:1188–1191.
13.
Jackson TL, Griffin L, Vote B, Hillenkamp J, Marshall J: An experimental method for testing novel retinal vital stains. Exp Eye Res 2005;81:446–454.
14.
Rodrigues EB, Meyer CH: Current dyes in chromovitrectomy: pros and cons. Am Physician 2005;14:29–38.
15.
Rodrigues EB, Meyer CH, Schmidt JC, Kroll P: Trypan blue stains epiretinal membrane but not internal limiting membrane. Br J Ophthalmol 2003;87:1431–1432.
16.
Meyer CH, Rodrigues EB, Kroll P: Trypan blue has a high affinity to cellular structures such as epiretinal membrane. Am J Ophthalmol 2004;137:207–208.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.